AGN-151607 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Operative Atrial Fibrillation
Conditions
Post-Operative Atrial Fibrillation
Trial Timeline
Mar 1, 2019 → Mar 6, 2023
NCT ID
NCT03779841About AGN-151607 + Placebo
AGN-151607 + Placebo is a phase 2 stage product being developed by AbbVie for Post-Operative Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT03779841. Target conditions include Post-Operative Atrial Fibrillation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03779841 | Phase 2 | Completed |
Competing Products
18 competing products in Post-Operative Atrial Fibrillation